{
    "clinical_study": {
        "@rank": "48587", 
        "arm_group": [
            {
                "arm_group_label": "Arginine rich nutritional supplement", 
                "arm_group_type": "Active Comparator", 
                "description": "237 ml of an arginine rich nutritional supplement 4 times a day for the five days preceding surgery."
            }, 
            {
                "arm_group_label": "No nutrional supplement", 
                "arm_group_type": "No Intervention", 
                "description": "No specific nutritional requirements have to be met in this group."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to characterize the immune-modulatory effects of\n      arginine-rich nutritional supplements in patients undergoing surgery. Numerical and\n      functional changes of all circulating immune cells will be assessed with mass cytometry."
        }, 
        "brief_title": "Immune-modulation Effects of an Arginine Rich Nutritional Supplement in Surgical Patients", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Cellular Immunity", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Colon surgery for cancer\n\n          2. Patients \u2265 18 and \u226465 years of age\n\n          3. Patients willing and able to sign an informed consent form and Health Insurance and\n             Portability Act (HIPAA) authorization and to comply with study procedures\n\n        Exclusion Criteria:\n\n          1. Patients on immune-suppressant therapy within the last 6 months (e.g. azathioprine or\n             cyclosporine)\n\n          2. Patients pretreated (6 months) or currently on chemotherapy for cancer\n\n          3. Patients on radiation therapy (within 6 months)\n\n          4. Patients on chronic medication with potential immune-modulatory effects (e.g. daily\n             oral morphine-equivalent intake > 30 mg)\n\n          5. Patients with metastatic disease\n\n          6. Patients with active infectious disease (within 2 months)\n\n          7. Patients with significant metabolic disease (e.g. diabetes type I)\n\n          8. Patients with clinically significant organ dysfunction including renal and hepatic\n             dysfunction\n\n          9. Patients with significant cardiovascular and respiratory comorbidities resulting in\n             impaired function and frailty\n\n         10. Patients with autoimmune disease (e.g. lupus)\n\n         11. Patients with Hx of substance abuse (e.g., alcoholism, drug dependency)\n\n         12. Undernourished patients as indicated by a weight loss >10% during the last 6 months\n\n         13. Patients with galactosemia\n\n         14. Patients who had undergone previous major abdominal surgery\n\n         15. Participation in another clinical trial of an investigational drug or device within\n             the last 30 days prior to the first day of study that, in the investigator's opinion,\n             would create increased risk to the participant or compromise the integrity or either\n             study\n\n         16. Pregnancy\n\n         17. Other conditions compromising a participant's safety or the integrity of the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01885728", 
            "org_study_id": "27485"
        }, 
        "intervention": {
            "arm_group_label": "Arginine rich nutritional supplement", 
            "description": "Impact is a nutritional supplement formulated with 18 grams of protein per serving and 24 essential nutrients including arginine.", 
            "intervention_name": "An arginine rich nutritional supplement", 
            "intervention_type": "Dietary Supplement", 
            "other_name": "'Impact' made by Nestle Corporation"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "August 19, 2013", 
        "location": {
            "contact": {
                "last_name": "Julian Silva, MA", 
                "phone": "650-724-9341"
            }, 
            "facility": {
                "address": {
                    "city": "Stanford", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "84305"
                }, 
                "name": "Stanford University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Controlled Study Evaluating the Immune-Modulatory Effects of Perioperative Administration of Arginine Rich Nutritional Supplements With Mass Cytometry in Patient Undergoing Surgery", 
        "other_outcome": {
            "measure": "Fractional and absolute expansion/contraction, functional status, and functional potency and capacity of cluster of differentiation 4 (CD4)+ and cluster of differentiation 8 (CD8)+ cells.", 
            "safety_issue": "No", 
            "time_frame": "Base line (prior to 1st administration of arginine supplement), immediately prior to surgery, 24 hours, 72 hours and 120 hours after surgery."
        }, 
        "overall_contact": {
            "email": "jsilva01@stanford.edu", 
            "last_name": "Julian Silva, MA", 
            "phone": "650-724-9341"
        }, 
        "overall_contact_backup": {
            "email": "mtingle@stanford.edu", 
            "last_name": "Martha S Tingle, RN", 
            "phone": "650-724-2742"
        }, 
        "overall_official": {
            "affiliation": "Stanford University SOM", 
            "last_name": "Martin S Angst, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The fraction of MDSCs will be quantified.", 
                "measure": "Changes in fractional representation of myeloid-derived suppressor cells (MDSC) from baseline.", 
                "safety_issue": "No", 
                "time_frame": "Base line (prior to 1st administration of arginine supplement), immediately prior to surgery, 24 hours, 72 hours and 120 hours after surgery."
            }, 
            {
                "description": "Intracellular phosphorylation events in MDSCs will be quantified.", 
                "measure": "Functional status change of myeloid-derived suppressor cells (MDSC) from baseline.", 
                "safety_issue": "No", 
                "time_frame": "Base line (prior to 1st administration of arginine supplement), immediately prior to surgery, 24 hours, 72 hours and 120 hours after surgery."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01885728"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Stanford University", 
            "investigator_full_name": "Martin Angst", 
            "investigator_title": "Professor of Anesthesia", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "Outcome measures include the 1) Surgical Recovery Scale, 2) Pain (11-point numerical pain rating scale), 3) Consumption of analgesic drugs.", 
            "measure": "Impact of surgery on clinical recovery using multiple clinical measures and a validated questionnaire.", 
            "safety_issue": "No", 
            "time_frame": "Daily for duration of hospital stay, then every 3 days trough postoperative week 5."
        }, 
        "source": "Stanford University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Martin Angst", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}